Four ongoing clinical trials are currently evaluating [68Ga]Ga-DOTATOC and [68Ga]Ga-DOTATATE in patients with meningiomas [82,83], pituitary adenomas [80], and other SSTR2-positive brain tumors [81]. Here, SSTR2 is linked to brain neoplasm.